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Finding biomarkers constitutes a crucial step for early detection of Alzheimer’s disease (AD). Brain imaging techniques have
revealed structural alterations in the brain that may be phenotypic in preclinical AD. The most prominent polymorphism that has
been associated with AD and related neural changes is the Apolipoprotein E (APOE) ε4. The translocase of outer mitochondrial
membrane 40 (TOMM40), which is in linkage disequilibrium with APOE, has received increasing attention as a promising gene in
AD.TOMM40alsoimpactsbrainareasvulnerableinAD,bydownstreamapoptoticprocessesthatforegoextracellularamyloidbeta
aggregation. The present paper aims to extend on the mitochondrial inﬂuence in AD pathogenesis and we propose a TOMM40-
induced disconnection of the medial temporal lobe. Finally, we discuss the possibility of mitochondrial dysfunction being the
earliest pathophysiological event in AD, which indeed is supported by recent ﬁndings.
1.Introduction
Alzheimer’s Disease (AD) is one of the leading causes of
dementiatodayanditposesanimmensesocietalchallengeas
the prevalence is expected to continue to rise [1]. This makes
it imperative to identify early preclinical changes in AD with
high accuracy, in order for intervention strategies to yield
eﬀective outcome and to allow aﬀectedindividualstopartake
inanactive treatmentplan[2–5]. AD is characterized by ear-
lypathologicalchangesinthebrain,includingsenileplaques,
neuroﬁbrillary tangles, synapse, and neuronal loss. Neuroﬁ-
brillary tangle formation may initiate in subcortical nuclei
suchasthedorsalrapheandlocuscoeruleus,priortospread-
ing to transentorhinal regions [6, 7]. Findings also support
that pathological changes in AD commence in the medial
temporallobe(MTL)[8–10],primarilyintheentorhinalcor-
tex (ERC) and hippocampus (HC) [11–13], which undergo
initial gray matter (GM) loss. Recently, attention has also
been directed towards the impact of pathological mecha-
nisms on white matter (WM), as up to 50% of AD cases
present with global WM deterioration in neuropathological
examinations [14, 15]. The temporal succession of GM and
WM changes in preclinical AD remains to be determined;
so far there is support for both primary and secondary WM
changes within the MTL [16, 17].
MCI is regarded as a prodromal state of AD, where indi-
viduals present with subjective memory complaints and/or
objective memory impairment, but are still intact in daily life
and do not meet current AD diagnostic criteria [2, 18, 19].
Amnestic type MCI (aMCI), where memory impairment is
considered predominant, has been proposed as a solution for
the diagnostic heterogeneity of the overall MCI criteria. The
construct of MCI allows for the clinical assessment of prod-
romal AD, where early interventions could have a beneﬁcial
eﬀect [20]. While promising, this therapeutic window is
hampered by the fact that not all individuals with MCI con-
vert to AD (6–25%), and almost half return to normal cogni-
tivehealthwithintheﬁrstyearoffollowup[2,21].Moreover,
caveats remain regarding MCI and its clinical usefulness, sig-
nifying that the most beneﬁcial use of the MCI criteria is by
combination with other structural, functional, neuropsy-
chological, genetic, and pathological biomarkers [22]. These2 International Journal of Alzheimer’s Disease
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Figure 1: Timeline of potential biomarkers in Alzheimer’s disease.
Prior to clinical diagnosis of AD, beta-amyloid (Aβ)a g g r e g a t i o n ,
micro- and macrostructural changes are thought to take place in a
timewise fashion (adapted from [23]). ∗Recent research points to a
shift in the biomarker timeline, with mitochondrial dysfunction
being primary in the pathophysiological cascade of AD, eventually
leading to micro- and macrostructural changes in the AD brain.
biomarkers were recently placed into a hypothetic biomarker
timeline by Jack and colleagues [23], who proposed that the
pathologicalcascadeinADcommenceswithamyloidandtau
pathology, followed by neural injury and dysfunction and
ﬁnally structural alterations (see Figure 1). Furthermore,
they hypothesize that β-amyloid deposition and the follow-
ing cascade occur earlier in Apolipoprotein (APOE) ε4c a r -
riers. Recent ﬁndings have shown brain and cognitive chan-
gesupto10yearspriortothediagnosisofAD,indicatingthat
the combination of biomarkers may provide an alternative
timeline [23–25]. A growing body of literature has empha-
sized the association between genetic and structural brain
biomarkers, with imaging quantitative traits within the MTL
beingamoreobjectiveoutcomethanclinicaldiagnosisalone.
The MTL may act as a mediator between genetic polymor-
phisms and the clinical expression of AD, indicating the
advantage of combined genetic and brain integrity biomark-
ers [26, 27].
APOE is one of the primary AD polymorphisms, associ-
ated not only with risk and age of onset, but also brain integ-
rityinAD[3,28,29].DuetoitsLinkageDisequilibrium(LD)
with APOE, Translocase of outer mitochondrial membrane
40 (TOMM40) was previously thought to have minimal in-
ﬂuence on the risk of AD [30, 31]. Nevertheless, it is now
established that TOMM40 inﬂuences onset of AD [31–37].
The TOMM40 gene holds promising biomarker properties
due to its negative impact on downstream apoptotic pro-
cesses within the mitochondrial system via possible amyloid
beta (Aβ) interplay [30, 38, 39]. Recently the mitochondrial
cascade hypothesis has received increasing support, propos-
ing that mitochondrial dysfunction is the key pathological
mechanism in AD, inﬂuencing brain structures known to be
vulnerableinAD[40,41].Weintendtoextendthesetheories
by presenting the mitochondrial disconnection model, an
adapted model for mitochondrial involvement in preclinical
AD. We also suggest a timeline shift in the biomarker realm,
away from the amyloid hypothesis, towards early and prima-
ry mitochondrial involvement in the pathophysiology of AD
(seeFigure 1).Theimplicationofmitochondrialdysfunction
in AD is currently supported by genetic and neuropatholog-
ical research [30, 39, 41] and has the possibility to shed light
on the primary biological insult in the disorder, as well as to
provide a new therapeutic window for AD [42, 43].
The present paper focuses on recent advances in neuro-
imaging and genetic biomarkers for preclinical AD. After an
overview of structural brain changes in early AD, we discuss
theinﬂuenceofAPOE andTOMM40,inaneﬀorttoapproxi-
mate the primary pathological cascade in AD. The mito-
chondrial disconnection model is an extension of previous
ﬁndings and is suggested as a workable hypothesis from
which the inﬂuential role of mitochondria on AD can be as-
sessed.
2. StructuralBrainChanges in
Early Alzheimer’s Disease
The consensus in the literature is that there is a long preclin-
ical phase of AD, with cognitive as well as structural brain
changes commencing years before clinical diagnosis of the
disorder[23,24,44].Indeed,signiﬁcantbrainatrophycanbe
observed in healthy individuals who will subsequently devel-
op MCI or AD, in comparison to stable controls, within the
bilateralmedial andlateraltemporal lobes,orbitofrontal cor-
tex, posterior cingulate, and precuneus [24]. Interestingly,
thesepreclinicalchangescorrespondtothepatternofGMal-
terations seen in diagnosed AD [15, 45], demonstrating that
earlyADtypepathologyispresentpriortoclinicalsymptoms
[24, 46].
Both MCI and AD have characteristic inﬂuence on struc-
tures in the brain, thereby making them dissociable from
nonpathological aging [45, 47]. Imaging studies have been
able to conﬁrm the Braak staging of neuropathology in AD
by showing early structural changes within the MTL (more
particularly the ERC and HC), prior to spreading to adjacent
cortices [10, 13, 48–50]. Looking closer at the HC, the lateral
CA1 subﬁeld is the most vulnerable in MCI and AD while
GM loss in the subiculum is associated with nonpathological
age-related changes, denoting region-speciﬁc changes within
the HC in AD [51]. Moreover, several studies have indicated
that the rate of atrophy within the MTL is faster for those
who convert from normal aging to MCI as well as from MCI
to AD in comparison to those who remain stable [52–54].
This shows that not only atrophy, but also the rate of atrophy
in the HC over time could serve as a potential biomarker of
preclinical AD. Structural changes in mild-to-moderate AD
also occur in areas that are strongly connected to the MTL,
such as the retrosplenial cortex, posterior cingulate, pre-
cuneus, and lateral posterior parietal regions [55, 56]. These
ﬁndings have been conﬁrmed in individuals with MCI,
w h e r em e d i a la n dl a t e r a lt e m p o r a la sw e l la sp a r i e t a la t r o p h y
was evident in individuals who converted from MCI to AD,
in comparison with those who remained stable [57].
Although the progression of WM alterations in the brain
is still unclear, damage to WM pathways within the MTL canInternational Journal of Alzheimer’s Disease 3
be detrimental according to the “disconnection hypothesis,”
stating that deterioration of WM tracts leads to subsequent
disconnection of the brain’s circuitry [11, 58]. Not only
might there be an overall disconnection, but a speciﬁc isola-
tion of the HC that may result from reduced WM integrity
within the MTL, mainly in the parahippocampal area, cin-
gulum, fornix, uncinate fasciculus, and perforant pathway
[59–61]. Moreover, an alteration in the WM of the precu-
neus, closely interconnected with the MTL, has also been ob-
served, resulting in the isolation of the hippocampus [59].
Researchers debate the sequential order of GM and WM de-
terioration in preclinical AD and the Wallerian degeneration
hypothesis stipulates that loss of WM integrity is secondary
to GM changes. In line with this hypothesis, research has
shown GM atrophy to be more eﬃcient in distinguishing
between AD patients and healthy controls. More speciﬁcally
it has been observed that right-sided hippocampal GM loss
is a better predictor of diagnostic status of AD than measures
of WM integrity [8]. Recently, this hypothesis was supported
in a study where primary GM degeneration in the HC was
followed by Wallerian degeneration of WM within the inter-
ammonic commissure, a pathway connecting the left and
right hippocampi [12]. Also similarly, Villain and colleagues
found HC atrophy to be followed by loss of WM integrity
in the uncinate fasciculus and cingulum bundle, which was
corroborated by metabolic alterations in connected cortical
areas, demonstrating a signiﬁcant disruption in connectivity
[61]. By contrast, WM deterioration has also been observed
in the absence of primary GM changes [60, 62]. For example,
in individuals with MCI and AD, loss of WM integrity has
beenseenintheperforantpathwayinabsenceofGMatrophy
[63]. Alteration of the perforant pathway, which connects
the ERC and the HC and constitutes a gateway to the limbic
system, may contribute to early and likely initial disconnec-
tion of the MTL in preclinical AD [60].
WM changes in small pathways of the brain, such as the
perforant pathway, are still arduous to discern with the cur-
rent available neuroimaging techniques. This is particularly
important in preclinical AD where the areas implicated are
small WM pathways within the MTL. Moreover, the lack of
longitudinal studies renders it diﬃcult to determine the tem-
poral order of GM and WM changes in the brain. It has been
pointed out that it is disadvantageous to consider the WM
changes in the brain in a dichotomized fashion [16, 17]. In-
stead,abalancedviewhasbeenproposedwherethetemporal
order of structural changes in the brain is dependent on
the retrogenesis of the speciﬁc structure [16, 64]. For in-
stance, in late myelinating pathways connected to the MTL
such as the inferior longitudinal fasciculus, primary loss of
WM integrity is thought to be of major inﬂuence. In early
myelinating pathways such as the cerebral peduncles, poste-
rior limb of internal capsule, and forceps major on the other
hand, WM degeneration is considered secondary to GM loss.
However, it has been proposed that within each brain area,
depending on its retrogenetic development, there is a ratio
between primary and secondary WM degeneration, possibly
explaining why the temporal order of GM and WM changes
in early AD has been diﬃcult to ascertain [16].
3.APOE and PreclinicalAlzheimer’s Disease
While research in the genetic ﬁeld has been fraught by small
eﬀectsizesanddiﬃcultyinreplicatingﬁndings,APOEhasre-
mained a robustly replicated susceptibility gene for AD [42,
65, 66]. Located on chromosome 19, APOE translates into
three common allelic variations ε2, ε3, and ε4[ 67], the ε4
being strongly associated with risk of developing AD [28,
68, 69]. Furthermore, the ε4 allele has been associated with
decreasedmemoryfunctioning,processingspeed,andlossof
GM and WM integrity [70–74]. The ε4 allele also modulates
risk of progression from MCI to AD. In eﬀect, a recent meta-
analysis demonstrated that the presence of one or two ε4
alleles increased the risk of MCI conversion to AD up to four
times. However, APOE as a risk factor has low predictivity
and sensitivity values as a diagnostic test for AD, leading to
the conclusion that APOE genotyping has limited value as a
diagnostic tool in clinical practice [75–77].
APOE appears to play an essential role for lipid metab-
olism within the Central Nervous System (CNS) and allelic
variations of the gene are thought to modulate neural repair,
lipid homeostasis, oxidative stress, and Aβ deposition [43,
68].Aslipidsareabundantinthebrainandessentialformye-
lination of axons, it comes as no surprise that APOE, being
themaincholesteroltransportlipoprotein,appearstoplayan
essential role in maintaining brain integrity [78]. Although
the mechanism behind the inﬂuence of APOE on the brain is
not fully elucidated, the protein appears to govern the eﬃ-
ciency of cholesterol delivery to neurons. Particularly, the
presence of an ε4 allele reduces the delivery of cholesterol,
consequently disturbing lipid homeostasis within the CNS
and triggering a cascade leading to the formation of amyloid
depositions [79]. The combined amyloid cascade hypothesis
[80] and APOE lipid recycling cascade models [81]p r o m o t e
a disturbance in lipid homeostasis as a source for AD pathol-
ogy [82]. While the amyloid cascade hypothesis has been
prominent throughout the last two decades, it was initially
based on studies with rare autosomal dominant variants of
AD and had pathophysiological shortcomings [83]. Indeed,
widespread amyloid deposition is present in AD, but there is
no consensus regarding the ﬁnite pathophysiological burden
of amyloid in the brain and it has been argued that amyloid
aggregation is a downstream process in AD not related to
clinical manifestation of the disorder [84]. While APOE may
inﬂuence the amyloid cascade in AD, other neuropatholog-
ical aspects of the polymorphism have been highlighted, in-
cluding inﬂuence on neuronal repair mechanisms and main-
tenance of synaptic connections [43]. One way of increasing
the predictability of the APOE polymorphisms is by combin-
ing genetic and structural brain biomarkers [27, 73].
4.APOE andStructuralIntegrity
Extensive research has been done on the genetic inﬂuence of
APOE polymorphisms on brain changes in preclinical AD
(Table 1). Support for the inﬂuence of APOE on AD-like
changes within the brain comes from a Genomewide Asso-
ciation Study (GWAS) on neuroimaging phenotypes in a
mixed sample of MCI and AD individuals [85]. The authors4 International Journal of Alzheimer’s Disease
found APOE to be one of the top ten genetic markers to in-
ﬂuence overall imaging phenotypes. Espeseth and colleagues
[86] demonstrated a modulatory eﬀect of APOE polymor-
phism on cortical thickness in healthy middle-aged adults.
Carriers of an ε4 allele showed accelerated cortical thinning
in speciﬁc regions known to structurally deteriorate in nor-
mal aging but also in AD such as prefrontal regions, para-
hippocampal cortex, and adjacent occipitotemporal areas
(fusiform and lingual gyri), but not the HC. Others have
found more region-speciﬁc inﬂuence of APOE on MTL areas
[29, 87, 88]. This eﬀect appears to be left lateralized with
the ε4 inﬂuence on HC volume [89]. The majority of ﬁnd-
ings converge towards a signiﬁcant impact of APOE poly-
morphism on GM integrity within the MTL, mainly the
HC.
Further, evidence for the inﬂuence of APOE on the MTL
comes from longitudinal studies on MCI and conversion to
AD (see Table 1). These have found that there is a genetic in-
ﬂuence of APOE not only on hippocampal GM loss, but also
on the rate of atrophy of the HC [88, 94]. Support for the
speciﬁc inﬂuence of APOE ε4 in MCI has been shown, as
aMCI individuals have been found more likely to have small-
er hippocampi and be carriers of at least one ε4 allele than
nonamnestic MCI individuals [94]. Also, MCI APOE ε4c a r -
riers express AD-type structural alterations such as atrophy
in MTL regions (ERC and HC). Those with MCI and an ε4
allele who convert to AD also show atrophy in frontal and
parietal cortices [48, 95]. Progressive MCI ε4 carriers show
global AD-type structural changes years before clinical diag-
nosisofAD[95].However,APOEε4doesnotpredictconver-
sion from MCI to AD, while ERC volume reduction at base-
line does [48]. Hence, it appears that while APOE may inﬂu-
ence structural integrity in areas that are vulnerable in the
preclinical stages in AD, APOE polymorphism has limited
predictive value on the conversion to AD. The latter ﬁnding
may, however, be biased by limited sample sizes. Thus, future
studiescombiningstructural,geneticandcognitivebiomark-
ers in larger samples may show enhanced predictability.
Given its hypothesized role as the brain’s main lipid
transporter [79], APOE impacts WM integrity in preclinical
AD [99]. Several studies have conﬁrmed both widespread
and localized WM changes throughout the brain in relation
to APOE polymorphism in healthy samples (see Table 1).
Persson and colleagues [97], for instance, demonstrated an
impact of APOE ε4 on the WM integrity of the posterior cor-
pus callosum and HC in healthy younger and older individu-
als, possibly reﬂecting preclinical signs of AD. Their ﬁndings
are supported by recently published data showing that the
presence of an ε4 allele exacerbates age-related WM changes
[73]. Moreover, it seems that late myelinating regions are
moresusceptibletoage-relatedlossofintegrityinε4carriers,
leading to progressive disconnection of the brain in APOE ε4
carriers [96].
In conclusion, inﬂuence of APOE on GM structural in-
tegrity has been consistently demonstrated in areas associ-
ated with preclinical AD. By contrast, little is known about
the genetic inﬂuence of APOE on WM changes in AD and
whether these changes are occurring sequentially or in a bal-
anced retrogenetic fashion.
5.TOMM40 and Preclinical
Alzheimer’sDisease
Missing heritability is increasingly debated in the literature,
as current genetic ﬁndings are not able to explain the full
extent of the genetic contribution to complex diseases such
as AD [65, 100, 101]. While larger sample sizes in GWAS are
suggested as a remedy for missing heritability, others suggest
that the answer resides in genetic polymorphisms that are
in LD with current known ones [65, 102–104]. TOMM40 is
becoming increasingly acknowledged as a prominent AD
gene [31–37]. In LD with APOE, TOMM40 could hold part
of the missing heritability that we are searching for in our
eﬀorts to map the genetic inﬂuences in AD. Moreover, taking
TOMM40 into consideration may contribute to a better un-
derstanding of the early and primary pathophysiological
cascade that takes place in the preclinical phases of the dis-
order.ThishypothesisissupportedbythefactthatTOMM40
asserts its inﬂuence on mitochondrial survival, a process in-
creasingly highlighted in the pathogenesis of AD [31, 105,
106]. Mitochondrial dysfunction has been associated with
several pathological processes in AD, including brain hy-
pometabolism, synaptic pathology, accumulation of Amy-
loid Precursor Proteins (APP), and Aβ inﬂux to the cell
[38, 39, 41]. Mitochondria have recently been implicated in
more complex signaling cascades, oxidative stress, and apop-
totic processes, indicating that mitochondria are not merely
a powerhouse of the cell, rather they appear to govern cell
death [107]. The notion of mitochondrial dysfunction in
aging and neurodegeneration is not new. In fact, malfunc-
tioningmitochondrialsystemshavebeenobservedinprema-
ture aging [105, 108] as well as neurodegenerative disorders
such as AD [40, 109, 110], Parkinson’s and Huntington’s dis-
ease [105] and appear to have an early and causal inﬂuence
onpathologicalprocessesinthebrain.Damageinmitochon-
dria may exert a speciﬁc inﬂuence on the pathophysiology of
AD through interplay with Aβ and its precursor, the APP
[111].
Mitochondria play an essential role in providing energy
to cells and are abundant in the neurons and synapses of the
CNS. Containing an outer and inner membrane, the organ-
elle is essential for the production of adenosine triphosphate
(ATP), which is the energy source of all cells [112]. The
outer mitochondrial membrane contains the translocase of
outer mitochondrial membrane pore subunit (Tom40). The
Tom40 channel forming subunit is one of the primary pores
via which proteins can readily enter the mitochondria. The
pore is governed by the TOMM40 gene and is essential for
mitochondrial survival as the majority of proteins that
enter the mitochondria pass through here [107, 113]. In
AD speciﬁcally, it has been hypothesized that mitochondria
exert neurotoxic inﬂuence by allowing the inﬂux of Aβ to
the cell via the Tom40 import pore. Passage of Aβ through
the Tom40 import pore increases Reactive Oxygen Species
(ROS) within the organelle. This increase is detrimental for
mitochondrial survival and energy production (ATP), ulti-
mately resulting in apoptotic processes of the cell [38, 111,
114]. Further ROS precipitating events include the ac-
cumulation of APP in mitochondrial import pores. ThisInternational Journal of Alzheimer’s Disease 5
Table 1: Genetic inﬂuence of APOE and TOMM40 on cerebral structural integrity.
Author Population Method Structural integrity Conclusion
Alzheimer’s Disease
APOE
Pievani et al.
2011 [29]
Across APOE
(ε4) n = 28
Volumetry
region based Smaller HC in APOE ε4+ ε4+ carriers have greater atrophy in the
HC.
Bendlin et al.
2010 [90]
Across
APOE(ε4) &
family history of
AD
n = 136
DTI
whole brain
Parental history of AD
Reduced FA in cingulum, tapetum,
uncinate fasciculus, HC, and adjacent
WM
No main eﬀect of APOE on WM, but
interaction with family history where
family history and ε4+ induced
reduced FA
While no main eﬀect of APOE was
observed onDTI measures, parental
history of AD was associated with reduced
WM integrity in brain areas deteriorated
in AD, which in turn interacted with
APOE.
Pievani et al.
2009 [91]
Across APOE
(ε4) n = 29
Volumetry
whole brain
APOE ε4+
Signiﬁcant atrophy in Bil temporal
lobes, occipital lobes, retrosplenial,
and posterior cingulate
Highest GM reduction >20%:
entorhinal cortex, anterior temporal
pole, superior and middle temporal
gyrus, ventral, and dorsal occipital
cortex
APOE ε4+ versus ε4−
Global GM reduction comparable
(RH: 14 versus 15%; LH: 16 versus
17%) ε4+ more atrophy in medial and
lateral temporal lobes, and right
occipital pole
After assessing the whole cortical mantle,
greater susceptibility of the MTL area was
found in APOE ε4 carriers.
Filippini et al.
2009 [92]
Across APOE
ε4 n = 100
Volumetry
whole brain
Additive model
GM reduction in Bil MTL (HC,
amygdala, parahippocampal gyrus),
fusiform cortex, and orbitofrontal
cortex
Genotypic model
Partially overlapping with additive,
extending from posterior MTL to
inferior lateral temporal cortex
Dose-dependent decrease in medial and
anterior temporal lobe volume per allelic
(ε4) load. Variable regional association
indicating that APOE works diﬀerently on
mechanisms of disease expression.
Barber et al.
1999 [93]
AD across
APOE ε4
n = 25
Visual scoring
MTL atrophy
WM HI
No signiﬁcant diﬀerences between ε4+
and ε4− on MTL atrophy, WM HI
APOE does not modulate white and gray
matter in AD. While APOE inﬂuences risk
of AD it appears not to modulate
pathological processes after diagnosis.
TOMM40
Potkin et al.
2009 [27]
AD (n = 229)
Healthy
Controls
(n = 194)
Volumetry
region-based
GWAS on HC QT
Case-control analysis identiﬁed APOE
and a new risk gene TOMM40 at 10−6
(10−11 at a haplotype level between
APOE & TOMM40 rs11556505)
25 SNPs were associated with QT HC,
including APOE
APOE has an eﬀect on brain atrophy
independent from overrepresentation in
AD. A novel risk gene, TOMM40,w a s
found to be associated with AD.
Mild Cognitive Impairment
APOE
Spampinato et
al. 2011 [88]
Stable versus
Progressive MCI
(n = 55) across
APOE (ε4)
Volumetry
whole brain
Longitudinal
Progressive APOEε4+
1 year prior to diagnosis: GM atrophy
in right temporal lobe, HC, insula
1 year FU: GM atrophy Bil HC,
parietal, insula, caudate Stable
APOEε4+
1 year FU GM atrophy Bil insula,
temporal lobe
APOEε4+ converters show early GM loss 1
year prior to diagnosis, and atrophy
progresses in ε4+ converters to AD.
However, some MTL atrophy is present in
APOE ε4+ nonconverters, reﬂecting
nonlinear eﬀects of APOE ε4.6 International Journal of Alzheimer’s Disease
Table 1: Continued.
Author Population Method Structural integrity Conclusion
He et al. 2009
[94]
MCI across
APOE n = 153
Volumetry
region based
Cross-sectional
Amnestic MCI
Signiﬁcantly reduced HC volume
Amnestic MCI individuals are more likely
to have MTL atrophy and to be carriers of
an APOE ε4 allele.
Tapiola et al.
2008 [48]
Stable versus
Progressive MCI
across APOE
n = 60
Volumetry
region based
Longitudinal
Progressive APOE ε4+
Reduced HC and ERC volume
While signiﬁcant atrophy was seen within
the MTL in APOE ε4+ carriers with
progressive MCI, the presence of an ε4
allele did not predict conversion to AD.
Hamalainen et
al. 2008 [95]
Stable versus
Progressive MCI
(n = 56) across
APOE (ε4)
Volumetry
whole brain
Longitudinal
Progressive APOE ε4+
Atrophy left inferior frontal gyrus,
intraparietal sulcus
Stable APOE ε4+
Atrophy right amygdala, anterior HC
APOE ε4+ converters display global
AD-like atrophy in frontal and parietal
cortices in comparison to ε4−, 2.5 years
prior to diagnosis of MCI.
APOE & TOMM40
Shen et al. 2010
[85]
APOE
n = 818
Volumetry
whole brain GWAS
Freesurfer QT: 56
areas VBM QT: 86
areas
APOE rs 429358 (ε4d e p e n d e n c e )
associated with whole brain Freesurfer
(15 regions) and VBM (4) phenotypes
at 10.6 signiﬁcance
TOMM40 rs2075650 associated with
Freesurfer (5) at 10−7 signiﬁcance
Freesurfer phenotypes
APOE associated with widespread
phenotypes
TOMM40 speciﬁcally associated with
left and right hippocampi and left
amygdala
While APOE is associated with widespread
cortical AD-like changes, TOMM40
appears to be associated mainly with MTL
phenotypes. Both APOE and TOMM40
were found among the top 5 SNPs in the
GWAS.
Normal Aging (only cross sectional)
APOE
Ryan et al. 2011
[73]
APOE
n = 126
Age range
52–92
DTI
region based
Signiﬁcant diﬀerences in ADC and FA
with increasing age in frontal WM,
lateral parietal WM, centrum
semiovale, genu and splenium of CC,
temporal stem WM
These age-related diﬀerences in WM
integrity were more prominent in ε4+
APOE ε4 exacerbates age-related WM
changes.
Zhang et al.
2011 [89]
APOE
n = 409
Age range
70–90
Volumetry
whole brain/region
based
Reduced GM volume in left HC in
APOE ε4+
No signiﬁcant diﬀerences in basal
forebrain
Only left hippocampal volume was
signiﬁcantly reduced in APOE ε4 carriers
and no diﬀerences were observed in the
basal forebrain area.
Espeseth et al.
2008 [86] APOE ε4+
(n = 37)
ε4− (n = 59)
Age range 48–75
Volumetry
whole brain
No group diﬀerences in total brain
volume, GM volume, WM volume
Cortical thickness ε4+
Thicker cortex in bilateral occipital
and occipito temporal areas, right
parahippocampal gyrus and frontal
areas
Thicker cortex in APOE ε4+ was found in
regions adjacent to those that show
accelerated age-related decline, indicating
that although well preserved now they may
eventually show cortical thinning.
Age related cortical thickness ε4+
Both ε4+ and ε4− have age-related
thinning in occipital and insula, but
ε4+ also show thinning of MTL
APOE ε4 may accelerate thinning in areas
that decline with aging (medial prefrontal,
pericentral cortex) as well as areas
susceptible to Aβ aggregation
(occipitotemporal, temporal cortex).
Bartzokis et al.
2006 [96]
APOE
n = 104
Age range 55–75
DTI
region based
APOE ε4+ showed steeper age-related
decline in radial diﬀusivity in late
myelinated regions frontal lobe and
genu of the CC
Late myelinated frontal regions appear
more susceptible to age-related breakdown
in APOE ε4+ carriers. This leads to
progressive disconnection of cerebral
networks in ε4 carriers and is supportive
of an anterior-posterior WM degeneration
gradient.International Journal of Alzheimer’s Disease 7
Table 1: Continued.
Author Population Method Structural integrity Conclusion
Persson et al.
2006 [97]
APOE
n = 60
Age range 49–79
DTI
region based
APOE ε4+ show reduced FA in
posterior CC, frontal fasciculus and
HC
Supportive of previous ﬁndings of reduced
FA in posterior CC, an area thought to be
associated with AD pathology.
TOMM40
Johnson et al.
2010 [98]
TOMM40 across
APOE ε3
n = 117 Age
range 40–65
Volumetry
whole brain
Dose-dependent increase in TOMM40
poly-T length associated with reduced
GM volume in ventral posterior
cingulate and medial ventral
precuneus
A subgroup of APOE ε3 carriers with long
poly-T length of the TOMM40 gene show
brain changes in areas associated with AD.
This indicates independent inﬂuence of
TOMM40.
ADC: Apparent diﬀusion coeﬃcient; APOE:A p o l i p o p r o t e i nE ;B i l :B i l a t e r a l ;C C :C o r p u sC a l l o s u m ;D T I :D i ﬀusion Tensor Imaging; ERC: Entorhinal cortex;
FA: Fractional Anisotropy; FU; Follow up; GWAS: Genome Wide Association Studies; GM: Gray matter; HC: Hippocampus; HI: Hyperintensities: LH: Left
Hemisphere; MD: Mean Diﬀusivity; MTL: Medial Temporal Lobe; QT: Quantitative Trait; RH: Right hemisphere; SNP: Single Nucleotide Polymorphism
(denoted rs); TOMM40: Translocase of outer mitochondrial membrane 40; WM: White matter.
accumulation of APP in import pores has been found in AD
brains, mainly in the frontal cortex, HC, and amygdala and
seen to vary with disease severity. Intriguingly, APOE ε3/ε4
carriers endorse the highest amount of mitochondrial APP,
suggesti v eofasynergeticeﬀectofmitochondrialdysfunction
in the presence of APOE [39]. Furthermore, it has been
shown that mitochondria have high intracellular Aβ accu-
mulation in AD [114]. It has been pointed out that Aβ accu-
mulation in mitochondria precedes extracellular Aβ deposi-
tion, which supports the role of mitochondria in the patho-
g e n e s i so fA D[ 38]. Moreover, TOMM40 has recently been
associated with CSF biomarkers including Aβ1−42, t-tau, and
p-tau [115]. To this end, the mitochondrial cascade hypoth-
esis is receiving increasing support throughout the literature,
thereby demonstrating the implications of mitochondrial
dynamicsintheearlypathophysiologyofAD.Thehypothesis
postulates that mitochondrial dysfunction precedes amyloid
insult to the brain and that mitochondrial injury is the pri-
mary source of pathology in AD [40, 116].
A recent neuropathological study, investigating the mor-
phology of mitochondria in AD brains, conﬁrmed the pres-
ence of mitochondrial pathology in brain areas typically
associatedwithAD-typepathology[41].Heremitochondrial
alterations of shape and size were observed in AD, in com-
parison to healthy controls, in the neurons of the HC, neo-
cortex, cerebellum, thalamus, pallidum, red nucleus, and lo-
cus coeruleus. As these assessments were conducted in post-
mortem AD brains, they more likely represent late patho-
physiological changes in AD. However, these ﬁndings are
suggestive of morphological changes in mitochondria, pos-
sibly acting causally in the pathogenesis of AD. While mito-
chondrial morphological changeswerenot limited tothe HC
[41], one would expect to see preclinical morphological
changes in the MTL, based on previous ﬁndings of mito-
chondrial- induced oxidative stress in preclinical dementia
[110] as well as ﬁndings of Aβ and mitochondrial interplay
[114].
Further support for mitochondrial involvement in AD
comes from genetic studies involving the TOMM40 gene.
Primarily Roses, and colleagues, the same group that dis-
covered the inﬂuence of APOE on AD [28], have been able
to demonstrate an association between a long poly-T repeat
of the TOMM40 gene with earlier age of onset of AD in
APOE ε3 carriers [30]. The TOMM40 poly-T length acts
either dependently or independently of APOE in the patho-
physiology of AD [117]. Moreover, studies focusing on Sin-
gle-NucleotidePolymorphisms(SNPs)havefoundanassoci-
ation between TOMM40 and AD. A recent case-control
study, comparing individuals with or without AD, showed
a highly signiﬁcant relationship between a TOMM40 SNP
(rs2075650) and AD. Interestingly, a haplotype of TOMM40
rs2075650, rs11556505, and APOE rs429358 held a stronger
association with AD than TOMM40 rs2075650 alone [85],
supporting Roses and colleagues ﬁndings of a synergetic ef-
fect of TOMM40 and APOE [30]. Moreover, a recent genet-
ic association study suggested that protein transport across
the mitochondrial membrane was implicated in the patho-
physiology of AD, and that TOMM40 is a likely contributor
to this detrimental transmembrane process within the mito-
chondria [118].
Although genetic studies on mitochondrial involvement
in AD are in their initial stages and replications are warrant-
ed, ﬁndings are supportive of previous postmortem, animal,
and pathological studies in AD suggesting a signiﬁcant in-
volvement of mitochondrial dysfunction in AD.
6.TOMM40 andStructuralIntegrity
Postmortem studies on mitochondrial morphology in the
HC [41] and the presence of APP in mitochondrial import
pores in the HC of AD patients [39] suggest that mitochon-
drial dysfunction may follow Braak staging of neuropathol-
ogy [8], with degeneration commencing in the MTL. By as-
sessing the mitochondrial inﬂuence on brain integrity in AD,
this temporal association can be further evaluated. Current
cross-sectional studies, focusing on the diﬀerential inﬂuence
of TOMM40 polymorphisms on the brain, oﬀer promising
insighttothislinkbetweengenesandneuropathologyinAD.
Johnson and colleagues [98] assessed the inﬂuence of
TOMM40 poly-T length on structural brain integrity and
cognition among APOE ε3 carriers. Analyses were restricted8 International Journal of Alzheimer’s Disease
to areas known to be vulnerable in AD including the amyg-
dala, HC, parahippocampal gyrus, posterior cingulated, and
precuneus. APOE ε3 carriers were divided according to
length variations of the TOMM40 polymorphisms, homozy-
gous short (SS), homozygous very long (VL), and heter-
ozygotes (S/VL). TOMM40 length variation was found to in-
ﬂuence episodic memory, which strongly depends on HC
integrity, exemplifying the genetic involvement of TOMM40
on AD-type cognitive deﬁcits. On the brain level, the poly-T
length seems to inﬂuence the integrity of the medial ventral
precuneus and posterior cingulate [98] ,w h i c hh a v eb e e n
showntobethesiteofearlyamyloidburdeninAD[55].This
conﬁrms previous ﬁndings, where the inﬂuence of TOMM40
poly-T length on AD onset has been shown [31] and sup-
ports the notion of mitochondrial inﬂuence in areas of the
brain that are vulnerable to AD. Hence, it appears that
healthy middle-aged individuals, who are APOE ε3h o m o z y -
gotes with a long poly-T of the TOMM40 gene, show an AD-
like proﬁle with regards to cognitive performance as well as
structural brain changes.
GWAS with HC volume as the phenotype supported
the inﬂuence of the TOMM40 gene on structural integrity
of areas implicated in AD. The authors found that three
TOMM40 risk alleles (rs157580, rs2075650, and rs11556505)
were overrepresented in the AD population as assessed by
case-control analysis [27]. Shortcomings of focusing on one
regioninthebrainwereoverturned,andarecentGWASused
whole brain imaging phenotypes in an attempt to under-
stand the association between TOMM40 and structural in-
tegrity [85]. Notably, this analysis resulted in a signiﬁcant
association of the TOMM40 gene (rs2075650) with left
amygdala and bilateral HC volume. Furthermore, compari-
son of healthy versus AD individuals revealed that TOMM40
was among the top 5 SNPs associated with whole brain
imaging phenotypes. This points to the selective inﬂuence of
TOMM40 on structural integrity in brain areas vulnerable
to AD and supports previous ﬁndings of high APP burden
in mitochondrial import pores in the HC and amygdala
[85].
In an eﬀort to examine the inﬂuence of TOMM40 in an
independent cohort, we used data from nondemented indi-
viduals (age range: 60–90 years), from the Swedish National
study on Aging and Care in Kungsholmen (SNAC-K) [119].
We assessed the genetic inﬂuence of the TOMM40
(rs2075650) gene on GM volume of the HC and episodic
memory performance [120]. We expected to observe an
APOE-independent negative inﬂuence of TOMM40 G( r i s k
allele) on both cognitive performance and volume. Based on
previous studies where APOE-independent TOMM40 inﬂu-
ence was assessed [117], we stratiﬁed our TOMM40 sample
across APOE. While we found no independent eﬀect of
TOMM40 on HC or ERC volume per se, we did observe that
the positive association between HC volume and episodic
memory was driven by the presence of at least one TOMM40
Ga l l e l ei nAPOE ε4 carriers. This ﬁnding indicates that
carriers of a TOMM40 Ga l l e l em a yb em o r ed e p e n d e n to n
HCvolumeforaccurateepisodicmemoryperformance.This
study suggests alterations within the mitochondrial system
in TOMM40 G allele carriers, perhaps resulting in early
morphometric alterations in mitochondrial shape and size.
These alterations are not inﬂuencing structure, but rather
the function of the HC, as assessed by episodic memory
performance. It is possible that we are observing functional
alterations at an early stage that are not yet accompanied by
signiﬁcantvolumetricchangesinaging.Asthetimelineshifts
to neurodegeneration, these functional changes may result
in substantial structural changes, supported by postmortem
ﬁndings of morphometric alterations in the mitochondria of
theHCinAD[41].FurthersupportisprovidedbyTOMM40
inﬂuenceonbrainintegrityandcognitionthatarevulnerable
in MCI and AD, as well as the overrepresentation of
TOMM40 risk alleles in AD population [27, 98]. Functional
changes within the HC might therefore be a primary sign of
mitochondrial degeneration in preclinical AD.
Overall, the studies that are available today point to a
selective inﬂuence of TOMM40 polymorphisms on structur-
al changes in AD vulnerable areas such as the HC, precuneus
and posterior cingulate cortex. To our knowledge, no studies
have been conducted on the genetic inﬂuence of TOMM40
on WM changes in the brain. While the majority of ﬁndings
concerning TOMM40 implicate GM changes, recent ﬁndings
from our laboratory suggest that mitochondrial dysfunction
might inﬂuencehippocampal functioning aswell, asassessed
using cognitive testing. These ﬁndings are supportive of a
prominent mitochondrial dysfunction in AD and are prom-
ising for the utilization of mitochondrial biomarkers for the
accuracy of early detection of preclinical AD.
7.The MitochondrialDisconnection Model
As an attempt to recapitulate and expand on ﬁndings in the
ﬁeld, we propose the mitochondrial disconnection model
(seeFigure 2).Thismodelisanadaptedrepresentationofthe
mitochondrial cascade in AD, and its downstream inﬂuence
onstructuralbrainchanges.Weproposethatthiscascadehas
a primary inﬂuence on GM structural integrity of regions of
the MTL, leading to disconnection and isolation of the MTL
as a result of deterioration of connecting WM tracts.
In the adapted mitochondrial disconnection model
TOMM40 acts via APOE-independent and -dependent path-
ways [31, 117]. Via APOE-independent pathways, TOMM40
regulates Aβ inﬂux to the mitochondria via the Tom40 outer
membrane pore. This notion is in line with postmortem
studies that have found APP lodged in the Tom40 channels
[39] as well as genetic studies suggesting that protein trans-
port across the mitochondrial membrane, that is governed
by the TOMM40 gene, is implicated in the pathophysiology
of AD [118]. Via APOE-dependent pathways, there may be
an interaction between APOE and TOMM40,w h i c hi nt u r n
may inﬂuence the Aβ inﬂux. APOE is essential in the clear-
ance and deposition of Aβ [79, 121–123] and has also been
shown to increase extracellular Aβ availability [39, 43]. This
increase in APOE-induced Aβ availability may allow for
al a r g e rp r o p o r t i o no fA β to ﬂow into the mitochondria
via Tom40 import pores [117]. APOE ε3/ε4 carriers have the
highest amount of mitochondrial APP, resulting in impaired
mitochondrial functioning, suggestive of the importance ofInternational Journal of Alzheimer’s Disease 9
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Figure 2: The mitochondrial disconnection model is an extension of the TOMM40-induced mitochondrial cascade in Alzheimer’s disease
(adapted from [31, 117]). TOMM40 governs the Tom40 complex on the outer mitochondrial membrane, allowing the inﬂux of amyloid
beta (Aβ) into the organelle. TOMM40 inﬂuence occurs either independently or dependently of APOE. Nevertheless, TOMM40-induced
inﬂux of Aβ to the cell starts downstream apoptotic processes via Reactive Oxygen Species (ROS), inducing cell death. We hypothesize that
this results in early functional and structural alterations within the Medial Temporal Lobe (MTL), primarily in the hippocampus (yellow).
Subsequent disconnection of the MTL, via deterioration of White Matter pathways such as the cingulum (green), fornix (red), and uncinate
fasciculus (blue) follow. Disconnection of the MTL may induce secondary functional and structural alteration in distal areas possibly as a
result of primary mitochondrial-induced cell death. (Brain graphic: courtesy of Michel Thiebaut de Schotten from the Natbrainlab, King’s
College, London, UK.).
mitochondrial dynamics, even in APOE ε3/ε4 carriers [39].
There is support in the literature for both APOE-inde-
pendentand-dependentpathways.Moreover,theTOMM40-
induced mitochondrial cascade is unlikely to be autonomous
of APOE, considering that APOE and TOMM40 are genet-
ically linked via LD. Nevertheless, we propose that even in
the APOE-dependent pathway, the role of TOMM40 is pri-
mary,asitinﬂuencesmitochondrialproteintransportviathe
Tom40 import pore.
Irrespectiveofthepathwaythroughwhichthemitochon-
drial cascade commences, the ﬂow of Aβ into the organelle
induces apoptotic processes. The latter functions by increas-
ing ROS within the mitochondria and has detrimental ef-
fects on cell survival within the MTL. As neurons contain
hundreds of mitochondria, apoptotic processes may occur in
a gradient fashion and might not inﬂuence neuronal struc-
ture initially. Morphometric changes have been seen in the
mitochondria of the HC in AD, but these take place in the
later stages of the disorder [41]. It is possible that early
TOMM40-induced mitochondrial changes likely inﬂuence
HC function, rather than its volume, evidenced by the triad
between TOMM40, HC volume, and episodic memory in
our aforementioned ongoing study [120]. This points to the
importance of combining genetic, structural, and cognitive
biomarkers to assess preclinical AD, as structural brain chan-
ges alone might not be suﬃcient for early and accurate pre-
diction of preclinical mitochondrial alterations in AD. We
suggest that functional changes in the HC, as a result of early
mitochondrial alterations, could be utilized as an additional
biomarker for preclinical AD. A timeline of mitochondrial
degeneration commencing with early functional changes
followed by structural changes within the brain can be hy-
pothesized.
Nevertheless, initial TOMM40-governed mitochondrial
insult has been found to take place in the HC [85]. Based on
previous ﬁndings that disconnection and isolation of the HC10 International Journal of Alzheimer’s Disease
plays an important role in the early pathophysiology of AD
[59–61], we hypothesize that WM changes of directly HC-
connected WM tracts including the fornix, cingulum, and
uncinate fasciculus follow in the mitochondrial cascade (see
Figure 2). Whether this occurs via primary Wallerian degen-
eration or balanced retrogenesis remains to be elucidated.
WM changes have been shown to be both primary and sec-
ondary to GM alterations in AD. The balance between pri-
mary or secondary WM degeneration within a certain region
maybedependentonthegradientofmitochondrialdysfunc-
tion within that area. This balance might not be the same
throughoutthebrain,asmitochondrialdysfunctionhasbeen
primarily observed in MTL structures such as the HC and
amygdala [39]. Future longitudinal studies will have to dis-
cern the temporal order of events and whether WM changes
in preclinical AD are dependent on mitochondrial dysfunc-
tion in the GM. Overall, a succession of mitochondrial dys-
functional events in the pathophysiology of AD is supported
not only by our ongoing study, but also by studies showing
mitochondrial damage in normal aging [124, 125]. The de-
gree of how widespread mitochondrial injury is in the brain
may be determined by the neurodegenerative status of the
individual and may follow Braak staging of pathology. That
would explain why we observe TOMM40-induced inﬂuence
on structural integrity of areas implicated in the early stag-
es of AD. Based on these ﬁndings, we propose that wide-
spread GM atrophy, seen in the later stages of AD, results
frommitochondria-induced MTLdisconnection viacortico-
limbic pathways. Disconnection of the MTL may induce
secondary functional and structural alteration in distal areas
[61].
Theproposedmodelisarepresentationofmitochondria-
induced disconnection as an early and accurate biomarker
for preclinical AD (see Figure 1). By this we expand on Jack
and colleagues [23] dynamic biomarker timeline and pro-
pose that mitochondrial dysfunction initiates the pathophys-
iological cascade in AD. Findings in support of this timeline
include the selective inﬂuence of TOMM40 on AD onset,
HC volume, and cognition over and beyond that of APOE
alone [27, 31, 85]. Moreover, mitochondrial Aβ aggregation
precedes extracellular Aβ aggregation [38] supporting the
mitochondrial cascade hypothesis rather than the amyloid
cascade hypothesis, as the primary event in the biomarker
timeline of AD. However, Jack and colleagues [23] pointed
out that Aβ depositions are also observed in asymptomatic
individuals, suggesting that the amyloid pathological process
might be part of the process of aging. While amyloid depo-
sitions precede the clinical outcome of AD, the high presence
of Aβ in healthy individuals suggests that other factors are
at play. Moreover, the amyloid cascade does not fall into line
withtheBraakstagingofpathology,wheretaupathologywas
proposed to precede amyloid aggregation and commence
within more basal midbrain structures [6, 7]. It has been
shown that both tau and amyloid have synergic eﬀects on
mitochondrial dysfunction[126],suggestingthatabiomark-
ertimelinebasedonmitochondrialpathologymightbemore
accurate in AD and would reconcile with Braak staging of
pathology that has been well supported by neuroimaging
studies.
8. Conclusion
There is increasing evidence for a primary mitochondrial
involvement in the pathophysiology of AD, as mitochondria
have been found to regulate cell death. Several studies have
highlighted the importance of altered mitochondrial dynam-
ics in the preclinical stages of AD, as well as mitochondri-
al involvement in structural brain changes within the MTL.
Perhaps more importantly, mitochondrial dysfunction ap-
pears to be primary to extracellular Aβ aggregation. These
ﬁndings demonstrate the necessity to direct attention away
from the amyloid cascade hypothesis towards the mitochon-
drialcascadehypothesis.MoreoverTOMM40shouldbecon-
sidered as a possible genetic modiﬁer of the biomarker time-
line in AD. The distinction between amyloid and mitochon-
drial cascades is not arbitrary with consideration to potential
biomarkers and treatments of AD. While “mitochondrial
protectors” as a potential treatment for AD are currently
underinvestigation[116],furtherstudiesareneededinorder
to assess mitochondrial dynamics in preclinical AD. Genetic
polymorphisms such as TOMM40 have the potential not
onlytoassessindividualsatrisk,butalsotoserveasbiomark-
ers in combination with current known structural and
cognitive ones. We propose the mitochondrial disconnection
model as a means by which the mitochondrial dynamics can
be assessed in preclinical AD.
Glossary
Allele: One of two versions of a gene, an allele is
a DNA coding that occupies a position on
a given chromosome.
Amyloid
cascade
hypothesis:
Proposes that the primary pathogenic
event in AD is alterations in Amyloid
Precursor Protein (APP) leading to the
aggregation of the amyloid beta (Aβ)
peptide.
Diﬀusion
tensor imaging
(DTI):
Imaging acquisition that generates
three-dimensional representation of the
degree and direction of water diﬀusion
(Brownian motion) in each voxel
(tensor). Images are derived from
computing 3 eigenvalues (λ1, λ2, λ3)
within each tensor.
Fractional
anisotropy
(FA):
DTI measure derived from the ratio of
eigenvalues in each voxel, providing
information about the directionality of
diﬀusion along a scale of 0 (isotropic
diﬀusion) to 1 (anisotropic diﬀusion)
where 0 represents completely random
diﬀusion indicative of damaged along
white matter ﬁbers.
Freesurfer: Software allowing assessment of
volumetric and cortical thickness
measures of the brain.
Genomewide
association
study
(GWAS):
Study by which the whole genome within
a population is assessed in an attempt to
identify common genetic associations
with diseases such as AD.International Journal of Alzheimer’s Disease 11
Linkage
disequilibrium
(LD):
Deﬁnesageneticregionthathashadmin-
imal recombination through ancestral
history,makinggeneswithinsuchregions
linked and dependent of each other.
Mean Diﬀusiv-
ity (MD):
A DTI measure derived from the mean of
the three eigenvalues that reﬂects mag-
nitude of water diﬀusion within a voxel,
without providing directionality. In-
creased MD is an indicator of tissue
degeneration.
Missing
heritability:
The notion that a large proportion of the
heritability of complex diseases such as
AD remains unknown. Current GWAS
have been able to identify genes with
small eﬀect sizes, leading us to ask where
in the genome the remaining heritability
is contained and why we cannot observe
them with current techniques.
Mitochondria: Areoftenreferredtoasthepowerhouseof
the cells, as they produce adenosine tri-
phosphate (ATP), the main energy source
of the cell. Mitochondria have an outer
and inner membrane, with the outer be-
ing permeable via active import channels
allowing the passage of proteins that
are essential for ATP. Mitochondria are
mainly independent organelles, as they
contain their own DNA. While they are
the major energy provider to the cells,
they are also critical for cell survival, cell
division, and neuronal death.
Mitochondrial
cascade
hypothesis:
Proposes that mitochondria are the pri-
mary source of pathology in AD, driving
Aβ plaque and neuroﬁbrillary tangle for-
mation.
Radial
diﬀusion:
Radial diﬀusivity (λ2 + λ3) represents
perpendicular diﬀusion across ﬁber path-
ways. Reduced radial diﬀusion has been
associated with myelin damage.
Reactive
oxygen species
(ROS):
A term that describes a variety of byprod-
ucts that are formed during the metabo-
lism of oxygen, otherwise known as free
radicals.Inmitochondriatheyareformed
as a result of respiration, and a disruption
in this balance by increased ROS within
mitochondria negatively inﬂuences cell
survival.
Region of
interest (ROI):
Imaging procedure that involves manual
outlining of an a priori brain region for
volumetric analysis.
Retrogenesis: The hypothesis that brain areas that were
early to develop are also the ﬁrst to show
AD-type pathology.
Single
nucleotide
polymorphism
(SNP):
Stands for a diﬀerence in DNA sequence,
occurring at a single nucleotide (A, T, C,
orG)onapairedchromosomeinanindi-
vidual and denoted by RS (related se-
quence).
Translocase
of outer mi-
tochondrial
membrane
(TOM):
Amajorimportchannelontheoutermito-
chondrial membrane that allows for the
inﬂux of proteins to the intermembrane
space of the organelle. Tom40 is the main
component of this channel serving as the
onlychannelbywhichproteinsentermito-
chondria.
Voxel Based
Morphometry
(VBM):
Automatic procedure that allows whole-
brain voxelwise analysis of tissue density
and volume.
Wallerian
Degeneration:
Is a model for axonal degeneration. Initial
neuronal damage is hypothesized to result
in distal axonal degeneration.
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